Description
The IGF 1 LR3 peptide is a modified analog of insulin-like growth factor 1 with structural changes that reduce its affinity for IGF-binding proteins compared with native IGF-1. It contains an arginine substitution at position 3 and an extended N-terminal sequence, giving the peptide a distinct profile for research into IGF receptor signaling, cellular growth pathways, nutrient response, and somatotropic axis activity.
The main IGF 1 LR3 benefits in experimental models relate to sustained growth-factor signaling and reduced binding-protein interactions. The IGF 1 LR3 half-life is longer than that of native IGF-1 under many research conditions, although the exact duration depends on the experimental model, matrix, and assay design. These properties make this peptide useful for controlled studies of prolonged IGF pathway activity and receptor responses.
Features
- Classification: Long R3 insulin-like growth factor 1 analog
- Structure: Modified IGF-1 peptide
- Modification: Arginine substitution at position 3 with N-terminal extension
- Binding Profile: Reduced affinity for IGF-binding proteins
- Research Focus: IGF receptor signaling, cellular growth response, and somatotropic-axis activity
Disclaimer: Supplied strictly for laboratory research. Not intended for human or veterinary administration, consumption, diagnosis, treatment, or therapeutic use.
Reviews
There are no reviews yet.